Close this search box.

Solid tumor immunotherapies headline ASCO’s first-in-human studies

ARTICLE | Product Development

A focus on first-in-class innovation and solid tumor applications

By Lauren Martz, Executive Director, Biopharma Intelligence

June 6, 2024 11:39 PM UTC

Finding ways to apply the modalities that have transformed the treatment of hematological malignancies to solid tumors, and advancing first-in-class innovation, are the themes emerging across the programs that are restocking clinical pipelines and defining emerging clinical trends.

BioCentury’s analysis of the first-in-human clinical trials described in the American Society of Clinical Oncology (ASCO) presentations and abstracts this year identified 143 therapies being tested in people for the first time. The analysis includes first-in-human trial readouts and descriptions of trials in progress, but does not include data from expansion cohorts when initial trial data were previously presented…